» Articles » PMID: 7855059

Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1994 Oct 1
PMID 7855059
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of protease inhibitors on the intestinal absorption of insulin were investigated in situ in closed small and large intestinal loops in rats, and the stability of insulin was examined in homogenates of the small and large intestine. The intestinal absorption of insulin was evaluated by its hypoglycemic effect. When insulin alone was administered into small or large intestinal loops, no marked hypoglycemic response was observed in either region. Of the coadministered protease inhibitors, soybean trypsin inhibitor (1.5, 10 mg/ml) marginally promoted insulin absorption from the large intestine, whereas aprotinin (10 mg/ml) did to a moderate degree. However, a significant hypoglycemic effect was obtained following large intestinal administration of insulin with 20 mM of Na-glycocholate, camostat mesilate and bacitracin, when compared with the controls. In contrast, we found little hypoglycemic effect following small intestinal coadministration of insulin with these protease inhibitors. In the stability experiment, bacitracin, camostat mesilate and Na-glycocholate were effective in reducing insulin degradation in both small and large intestinal homogenates. It was found that the reduction in the proteolytic rate of insulin was related to the decrease in plasma glucose concentration by these protease inhibitors in the large intestine. These findings suggest that coadministration of protease inhibitors would be useful for improving the large intestinal absorption of insulin.

Citing Articles

Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives.

Ding B, Zhu Z, Guo C, Li J, Gan Y, Yu M Acta Pharm Sin B. 2024; 14(5):2006-2025.

PMID: 38799624 PMC: 11120284. DOI: 10.1016/j.apsb.2024.02.019.


Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.

Nhan N, Yamada T, Yamada K Int J Mol Sci. 2023; 24(16).

PMID: 37629112 PMC: 10454368. DOI: 10.3390/ijms241612931.


EpCAM proteolysis and release of complexed claudin-7 repair and maintain the tight junction barrier.

Higashi T, Saito A, Fukazawa Y, Furuse M, Higashi A, Ono M J Cell Biol. 2022; 222(1).

PMID: 36378161 PMC: 9671161. DOI: 10.1083/jcb.202204079.


Gastrobodies are engineered antibody mimetics resilient to pepsin and hydrochloric acid.

Wicke N, Bedford M, Howarth M Commun Biol. 2021; 4(1):960.

PMID: 34381153 PMC: 8358037. DOI: 10.1038/s42003-021-02487-2.


Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?.

Zhang T, Tang J, Fei X, Li Y, Song Y, Qian Z Acta Pharm Sin B. 2021; 11(3):651-667.

PMID: 33777673 PMC: 7982494. DOI: 10.1016/j.apsb.2020.08.016.


References
1.
Yamamoto A, Luo A, Lee V . The ocular route for systemic insulin delivery in the albino rabbit. J Pharmacol Exp Ther. 1989; 249(1):249-55. View

2.
Okada H, Yamazaki I, Ogawa Y, Hirai S, YASHIKI T, Mima H . Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement. J Pharm Sci. 1982; 71(12):1367-71. DOI: 10.1002/jps.2600711214. View

3.
Yamamoto A, Umemori S, Muranishi S . Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J Pharm Pharmacol. 1994; 46(1):14-8. DOI: 10.1111/j.2042-7158.1994.tb03712.x. View

4.
SAFFRAN M, Kumar G, Savariar C, Burnham J, Williams F, Neckers D . A new approach to the oral administration of insulin and other peptide drugs. Science. 1986; 233(4768):1081-4. DOI: 10.1126/science.3526553. View

5.
Roth R . Bacitracin: an inhibitor of the insulin degrading activity of glutathione-insulin transhydrogenase. Biochem Biophys Res Commun. 1981; 98(2):431-8. DOI: 10.1016/0006-291x(81)90858-5. View